TME Pharma N.V. (EPA:ALTME)

France flag France · Delayed Price · Currency is EUR
0.0706
-0.0029 (-3.95%)
Mar 6, 2026, 5:02 PM CET
-1.94%
Market Cap 6.64M
Revenue (ttm) 27.00K
Net Income (ttm) -4.58M
Shares Out 94.09M
EPS (ttm) -0.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 257,922
Average Volume 274,743
Open 0.0701
Previous Close 0.0735
Day's Range 0.0692 - 0.0725
52-Week Range 0.0490 - 0.1480
Beta 0.77
RSI 47.99
Earnings Date Apr 23, 2026

About TME Pharma

TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The company’s Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, and glioblastoma. It also developing NOX-E36, which has completed Phase 1/2a clinical trial for the treatme... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1997
Employees 12
Stock Exchange Euronext Paris
Ticker Symbol ALTME
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.